Ligosan (Doxycycline Hyclate)

Doxycycline hyclate binds to the bacterial 30S ribosomal subunit, blocking the addition of aminoacyl‑tRNA and halting protein synthesis. This bacteriostatic effect limits bacterial growth and also reduces inflammatory mediators in periodontal tissues, helping to control infection and tissue damage.

The dosage and frequency of Ligosan are determined by the prescribing clinician based on the severity of the periodontal condition, patient age, renal function, and other clinical factors. No fixed regimen is provided here; the prescriber sets the appropriate regimen.

Ligosan is classified as Pregnancy Category D, indicating potential risk to the fetus; it should be used only when the expected benefit justifies the risk. Doxycycline can be excreted in breast milk, so caution is advised for nursing mothers, and alternative therapy may be considered.

To order Ligosan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Ligosan’s doxycycline hyclate offers a broad spectrum of activity against gram‑positive and gram‑negative oral pathogens and adds matrix metalloproteinase inhibition, which may benefit tissue preservation. Compared with minocycline, another tetracycline used in dentistry, doxycycline generally has a lower risk of pigmentation and may be better tolerated in topical formulations.

Ligosan should be stored at ambient temperature, below 25 °C, in its original container. Protect the product from moisture and direct light to maintain stability. Keep out of reach of children and avoid exposing the medication to extreme temperatures.

Ligosan is applied directly to the affected periodontal sites, usually by a dental professional. The topical gel or paste is placed into periodontal pockets or onto the gingival margin according to the prescriber’s instructions, allowing the medication to act locally on the bacterial biofilm.

The most serious adverse reactions include severe allergic responses such as rash, swelling, or anaphylaxis; Clostridioides difficile‑associated colitis presenting as persistent diarrhea; and hepatotoxicity indicated by elevated liver enzymes. Patients should be instructed to seek immediate medical attention if any of these symptoms occur.

Ligosan is contraindicated in patients with a known hypersensitivity to doxycycline, other tetracyclines, or any component of the formulation. It should also be avoided in individuals with severe renal impairment unless dose adjustments are made, and in pregnant women unless the therapeutic benefit outweighs the potential fetal risk.